FOUR-YEAR FOLLOW-UP OF PREGNANCY-ASSOCIATED OSTEOPOROSIS: A CASE REPORT
| Autor: | Satoru Kayama, Junichi Handa, Kenji Ichiji, Naoto Takahashi, Hironari Fukuda, Shinichi Konno, Itaru Arai |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
musculoskeletal diseases
bisphosphonate medicine.medical_specialty medicine.medical_treatment Osteoporosis long-term follow-up conservative treatment Young Adult Lumbar Pregnancy Teriparatide Humans Medicine 493.6 teriparatide Bone mineral Bone Density Conservation Agents medicine.diagnostic_test business.industry Magnetic resonance imaging General Medicine Bisphosphonate Pregnancy-associated osteoporosis medicine.disease Low back pain Surgery Pregnancy Complications Risedronate Sodium Female medicine.symptom business Low Back Pain Risedronic Acid Follow-Up Studies medicine.drug |
| Zdroj: | FUKUSHIMA JOURNAL OF MEDICAL SCIENCE. 60:175-180 |
| ISSN: | 2185-4610 0016-2590 |
| DOI: | 10.5387/fms.2014-14 |
| Popis: | A 22-year-old woman presented with complaints of severe pain in a wide region of the thoracolumbar spine. She developed severe pain in the thoracolumbar spine region 2 months after her first delivery and was referred 1 month later. A lateral thoracic X-ray showed depressed degenerative vertebrae (T7, T9). One month after the initial examination, thoracic sagittal magnetic resonance imaging showed low intensity areas on T1-weighted imaging and iso-high intensity areas on T2-weighted imaging at T5, 7, 8, 9 and 11. Bone mineral density measured by ultrasound was low (%YAM 76%). The bone metabolic markers were high, suggesting accelerated osteoclast activity. These findings prompted a diagnosis of pregnancy-associated osteoporosis. She was asked to stop breastfeeding and to wear a lumbar brace, and treatment with nutritional calcium, activated vitamin D3, and risedronate sodium was started. Her low back pain almost disappeared after treatment. Bone metabolic markers showed normalization 8 months after the initial examination. Risedronate sodium was stopped 2 years and 2 months after the initial examination. Teriparatide treatment was started because her bone mineral density remained low; however, the osteoblast marker P1NP was not increased 5 months after the start of teriparatide treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|